Southwest Oncology Group Experience with Intraperitoneal Chemotherapy of Ovarian Cancer

摘要: Ovarian cancer (OC) is the leading cause of gynecologic death in United States, and over 14,000 women will die this disease 1999 (1). During past two decades, median survival has improved dramatically with advent platinum-and paclitaxel-based chemotherapy. In early 1970s, a woman stage III was approx 12 mo (2). With currently available therapies, been extended to longer than 45 for patients optimal surgical resections during initial exploratory laparotomy (3,4). Unfortunately, despite significant gains therapeutic efficacy high response rates primary chemotherapy regimens, majority advanced OC develop drug-resistant tumors, eventually succumb their disease.